StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) PT Raised to $400 at Oppenheimer
January 26, 2018 6:46 AM
Oppenheimer raised its price target on Biogen (NASDAQ: BIIB) to $400.00 (from $380.00) while maintaining a Outperform rating.Analyst Jay Olson ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Biogen (BIIB) PT Raised to $373 at Deutsche Bank
January 26, 2018 6:13 AM
Biogen (BIIB) PT Raised to $403 at BMO Capital on 4Q Report; '2018 Guidance Above Street With Room to Grow'
January 25, 2018 3:48 PM
Biogen (BIIB) PT Raised to $408 at Cowen
January 25, 2018 1:12 PM
Biogen (BIIB) Misses Q4 EPS by 19c, Revenue Beats; Offers Outlook
January 25, 2018 6:31 AM
Biogen Reports Record Revenues for Both the Full Year and Fourth Quarter of 2017, $12.3 Billion and $3.3 Billion, Respectively
January 25, 2018 6:29 AM
